Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeAgeTrial IDs
Phase IIITreatment18 and overRTOG 0924
NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588

Trial Description

Summary

This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer. Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.

Further Study Information

PRIMARY OBJECTIVE:

I. Demonstrate that prophylactic, neoadjuvant, androgen-deprivation therapy (NADT) and whole-pelvic radiation therapy (WPRT) will result in improvement in overall survival (OS) of patients with “unfavorable” intermediate-risk or “favorable” high-risk prostate cancer compared to NADT and high-dose prostate and seminal vesicle (SV) radiation therapy (prostate [P] + SV radiation therapy [RT]) using intensity-modulated radiotherapy (IMRT) or external-beam RT (EBRT) with a high-dose rate (HDR) or a permanent prostate (radioactive seed) implant (PPI) boost.

SECONDARY OBJECTIVES:

I. Demonstrate that prophylactic WPRT improves biochemical control.

II. Distant metastasis (DM)-free survival.

III. Cause-specific survival (CSS).

IV. Compare acute and late treatment-adverse events between patients receiving NADT and WPRT versus NADT + P and SV RT.

V. Determine whether health-related quality of life (HRQOL), as measured by the Expanded Prostate Cancer Index Composite (EPIC), significantly worsens with increasing aggressiveness of treatment (i.e., Arm 2, NADT + WPRT). (closed to patient accrual 3/9/15)

VI. Determine whether more aggressive treatment (Arm 2, NADT + WPRT) is associated with a greater increase in fatigue (Patient-Reported Outcome Measurement Information System [PROMIS] Fatigue Short Form) from baseline to last week of treatment, and a greater increase in circulating inflammatory markers (interleukin [IL]-1, IL-1 receptor antagonist [ra], IL-6, tumor necrosis factor [TNF]-alpha, and C-reactive protein). (closed to patient accrual 3/9/15)

VII. Demonstrate an incremental gain in OS and CSS with more aggressive therapy that outweighs any detriments in the primary generic domains of HRQOL (i.e., mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). (closed to patient accrual 3/9/15)

VIII. Determine whether changes in fatigue from baseline to the next three time points (week prior to RT, last week of treatment, and 3 months after treatment) are associated with changes in circulating cytokines, mood, sleep, and daily activities across the same time points.

IX. Collect paraffin-embedded tissue blocks, plasma, whole blood, and urine for planned and future translational research analyses.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

All patients receive neoadjuvant androgen-deprivation therapy comprising bicalutamide orally (PO) once daily (QD) or flutamide PO thrice daily (TID) for 6 months, and luteinizing hormone-releasing hormone (LHRH) agonist/antagonist therapy comprising leuprolide acetate, goserelin acetate, buserelin, triptorelin, or degarelix subcutaneously (SC) or intramuscularly (IM) every 1 to 3 months beginning 2 months prior to radiotherapy and continuing for 6 or 32 months. Radiotherapy begins within 8-10 weeks after beginning LHRH agonist/antagonist injection.

ARM I: Patients undergo high-dose radiotherapy of the prostate and seminal vesicles using IMRT* or 3D-conformal radiation therapy (3D-CRT)* QD, 5 days a week, for approximately 9 weeks. Patients may also undergo PPI brachytherapy or high-dose rate brachytherapy (iodine I 125 or palladium Pd 103 may be used as the radioisotope).

ARM II: Patients undergo WPRT* (3D-CRT or IMRT) QD, 5 days a week, for approximately 9 weeks. Patients may also undergo brachytherapy as in Arm I.

NOTE: * Patients undergoing brachytherapy implant receive 5 weeks of IMRT, 3D-CRT, or WPRT.

After completion of study treatment, patients are followed up every 3 months for 1 year, every 6 months for 3 years, and then yearly thereafter.

Eligibility Criteria

Inclusion Criteria:

Hemoglobin (Hgb) >= 8.0 g/dL (Note: the use of transfusion or other intervention to achieve Hgb >= 8.0 g/dL is acceptable)

Zubrod performance status 0-1 (unless otherwise specified)

No evidence of bone metastases (M0) on bone scan within 120 days prior to registration (sodium fluoride [NaF] positron emission tomography [PET]/CT is an acceptable substitute)

Equivocal bone scan findings are allowed if plain films (or CT or magnetic resonance imaging [MRI]) are negative for metastasis

Clinically negative lymph nodes as established by imaging (pelvic and/or abdominal computed tomography [CT] or magnetic resonance [MR]), (but not by nodal sampling, or dissection) within 90 days prior to registration

Patients with lymph nodes equivocal or questionable by imaging are eligible if the nodes are =< 1.5 cm

Absolute neutrophil count (ANC) >= 1,500/mm³

History/physical examination (to include at a minimum digital rectal examination of the prostate and examination of the skeletal system and abdomen) within 90 days prior to registration

Platelets >= 100,000/mm³

Patient must be able to provide study specific informed consent prior to study entry

Baseline serum PSA value performed with a Food and Drug Administration (FDA)-approved assay (e.g., Abbott, Hybritech) within 120 days prior to registration

Study entry PSA should not be obtained during the following time frames:

10-day period following prostate biopsy

Following initiation of hormonal therapy

Within 30 days after discontinuation of finasteride

Within 90 days after discontinuation of dutasteride

Pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate- to high-risk for recurrence as determined by one of the following combinations:

Gleason score 7-10 + T1c-T2b (palpation) + prostate-specific antigen (PSA) < 50 ng/mL (includes intermediate- and high-risk patients)

Gleason score 6 + T2c-T4 (palpation) + PSA < 50 ng/mL OR Gleason score 6 + >= 50% (positive) biopsies + PSA < 50 ng/ml

Gleason score 6 + T1c-T2b (palpation) + PSA > 20 ng/mL

Patients previously diagnosed with low risk prostate cancer undergoing active surveillance who are re-biopsied and found to have unfavorable intermediate risk disease or favorable high risk disease according to the protocol criteria are eligible for enrollment within 180 days of the repeat biopsy procedure

Exclusion Criteria:

Previous hormonal therapy, such as LHRH agonists (e.g., leuprolide, goserelin, buserelin, triptorelin) or LHRH antagonist (e.g. degarelix), anti-androgens (e.g., flutamide, bicalutamide, cyproterone acetate), estrogens (e.g., diethylstilbestrol [DES]), or surgical castration (orchiectomy)

Patients who are sexually active and not willing/able to use medically acceptable forms of contraception

Severe, active co-morbidity, defined as follows:

Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months

Transmural myocardial infarction within the last 6 months

Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration

Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration

Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects or severe liver dysfunction

Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients

Use of dutasteride or dutasteride/tamsulosin (Jalyn) within 90 days prior to registration

Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both LHRH agonist and oral anti-androgen) is =< 45 days prior to the date of registration

Use of finasteride within 30 days prior to registration

Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy

Prior invasive (except non-melanoma skin cancer) malignancy unless disease-free for a minimum of 3 years (1095 days) not in the pelvis (for example, carcinoma in situ of the oral cavity is permissible; however, patients with prior history of bladder cancer are not allowed); prior hematological (e.g., leukemia, lymphoma, myeloma) malignancy not allowed

Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer

Previous or concurrent cytotoxic chemotherapy for prostate cancer; note that prior chemotherapy for a different cancer is allowable

Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy fields

Prior allergic reaction to the hormones involved in this protocol

Patients status post a negative lymph node dissection are not eligible

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

NRG Oncology

  • National Cancer Institute
Mack Roach, Principal Investigator

Trial Sites

U.S.A.

Alabama
Mobile

University of South Alabama Mitchell Cancer Institute

Roger Ove
Ph: 800-641-2422

Roger Ove
Principal Investigator

Alaska
Anchorage

Providence Alaska Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Fairbanks

Fairbanks Memorial Hospital

Huong Thanh Pham
Ph: 206-342-6954
Email: vmmc.cancer_clinical_research@VirginiaMason.org

Huong Thanh Pham
Principal Investigator

Arizona
Peoria

Arizona Center for Cancer Care-Peoria

Terry Tak-Keon Lee
Ph: 623-773-2873

Terry Tak-Keon Lee
Principal Investigator

Phoenix

Saint Joseph's Hospital and Medical Center

David G. Brachman
Ph: 877-602-4111

David G. Brachman
Principal Investigator

Scottsdale

21st Century Oncology-Scottsdale

Steven E. Finkelstein
Ph: 888-823-5923
Email: ctsucontact@westat.com

Steven E. Finkelstein
Principal Investigator

Arizona Oncology Services Foundation

David G. Brachman
Ph: 877-602-4111

David G. Brachman
Principal Investigator

Tucson

Arizona Oncology Associates-West Orange Grove

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

California
Auburn

Sutter Cancer Centers Radiation Oncology Services-Auburn

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Burbank

Providence Saint Joseph Medical Center/Disney Family Cancer Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Cameron Park

Sutter Cancer Centers Radiation Oncology Services-Cameron Park

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Fresno

Fresno Cancer Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Greenbrae

Marin General Hospital

Lloyd T. Miyawaki
Ph: 415-925-7325

Lloyd T. Miyawaki
Principal Investigator

La Jolla

UC San Diego Moores Cancer Center

Mack Roach
Ph: 877-827-3222
Email: mroach@radonc.ucsf.edu

Mack Roach
Principal Investigator

Long Beach

Veterans Administration Long Beach Medical Center

Samar H. Azawi
Ph: 562-826-8000

Samar H. Azawi
Principal Investigator

Los Angeles

Cedars-Sinai Medical Center

Howard M. Sandler
Ph: 310-423-8965

Howard M. Sandler
Principal Investigator

Modesto

Memorial Medical Center

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Oakland

Alta Bates Summit Medical Center - Summit Campus

James Henry Feusner
Ph: 510-450-7600

James Henry Feusner
Principal Investigator

Kaiser Permanente Oakland-Broadway

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Palm Springs

Desert Regional Medical Center

Amir Lavaf
Ph: 760-416-4730

Amir Lavaf
Principal Investigator

Palo Alto

Stanford Cancer Institute

Mark K. Buyyounouski
Ph: 650-498-7061
Email: ccto-office@stanford.edu

Mark K. Buyyounouski
Principal Investigator

Paradise

Feather River Cancer Center

Sam Mazj
Ph: 530-876-7995
Email: haleew@ah.org

Sam Mazj
Principal Investigator

Pomona

Pomona Valley Hospital Medical Center

Yallapragada S. (Ram) Rao
Ph: 909-865-9555

Yallapragada S. (Ram) Rao
Principal Investigator

Rancho Cordova

Kaiser Permanente-Rancho Cordova Cancer Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Rohnert Park

Rohnert Park Cancer Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Roseville

Sutter Cancer Centers Radiation Oncology Services-Roseville

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

The Permanente Medical Group-Roseville Radiation Oncology

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Sacramento

South Sacramento Cancer Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Sutter General Hospital

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

University of California Davis Comprehensive Cancer Center

Richard K. Valicenti
Ph: 916-734-3089

Richard K. Valicenti
Principal Investigator

San Diego

University of California San Diego

Loren K. Mell
Ph: 858-822-5354
Email: cancercto@ucsd.edu

Loren K. Mell
Principal Investigator

San Francisco

UCSF Medical Center-Mount Zion

Mack Roach
Ph: 877-827-3222

Mack Roach
Principal Investigator

Santa Clara

Kaiser Permanente Medical Center - Santa Clara

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

South San Francisco

Kaiser Permanente Cancer Treatment Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Truckee

Tahoe Forest Cancer Center

Richard K. Valicenti
Ph: 916-734-3089

Richard K. Valicenti
Principal Investigator

Vacaville

Sutter Cancer Centers Radiation Oncology Services-Vacaville

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Colorado
Aurora

Rocky Mountain Cancer Centers-Aurora

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

University of Colorado Cancer Center - Anschutz Cancer Pavilion

Brian Dennis Kavanagh
Ph: 720-848-0650

Brian Dennis Kavanagh
Principal Investigator

Boulder

Rocky Mountain Cancer Centers-Boulder

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Denver

Porter Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Greeley

North Colorado Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Longmont

Longmont United Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Loveland

McKee Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Parker

Parker Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Connecticut
Hartford

Saint Francis Hospital and Medical Center

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Middletown

Middlesex Hospital

Susanna Hong
Ph: 860-358-2058

Susanna Hong
Principal Investigator

Delaware
Newark

Christiana Care Health System-Christiana Hospital

Adam Raben
Ph: 302-733-6227

Adam Raben
Principal Investigator

Helen F Graham Cancer Center

Adam Raben
Ph: 302-733-6227

Adam Raben
Principal Investigator

District of Columbia
Washington

Washington Hospital Center

Pamela D. Randolph-Jackson
Ph: 202-877-8839

Pamela D. Randolph-Jackson
Principal Investigator

Florida
Jacksonville

Baptist Cancer Institute

Michael Ray Olson
Ph: 904-202-7051

Michael Ray Olson
Principal Investigator

Georgia
Atlanta

Emory University/Winship Cancer Institute

Ashesh B. Jani
Ph: 404-778-1868

Ashesh B. Jani
Principal Investigator

Grady Health System

Ashesh B. Jani
Ph: 404-778-1868

Ashesh B. Jani
Principal Investigator

Piedmont Hospital

Adam Wayne Nowlan
Ph: 404-425-7943
Email: ORS@piedmont.org

Adam Wayne Nowlan
Principal Investigator

Saint Joseph's Hospital of Atlanta

Ashesh B. Jani
Ph: 404-778-1868

Ashesh B. Jani
Principal Investigator

Columbus

John B Amos Cancer Center

Douglas F. Ciuba
Ph: 706-660-6404

Douglas F. Ciuba
Principal Investigator

Decatur

Atlanta VA Medical Center

Scott Edelman
Ph: 404-321-6111ext7632

Scott Edelman
Principal Investigator

Savannah

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

John A. Pablo
Ph: 800-622-6877

John A. Pablo
Principal Investigator

Hawaii
Ewa Beach

The Cancer Center of Hawaii-Leeward

Paul Arthur DeMare
Ph: 808-545-8548

Paul Arthur DeMare
Principal Investigator

Honolulu

Queen's Medical Center

Paul Arthur DeMare
Ph: 808-545-8548

Paul Arthur DeMare
Principal Investigator

The Cancer Center of Hawaii-Liliha

Paul Arthur DeMare
Ph: 808-545-8548

Paul Arthur DeMare
Principal Investigator

Idaho
Boise

Saint Alphonsus Cancer Care Center-Boise

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Post Falls

Kootenai Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Illinois
Arlington Heights

Northwest Community Hospital

Stephen Schaeffer Nigh
Ph: 847-618-4968

Stephen Schaeffer Nigh
Principal Investigator

Aurora

Rush - Copley Medical Center

Sinisa Stanic
Ph: 800-446-5532

Sinisa Stanic
Principal Investigator

Chicago

John H Stroger Jr Hospital of Cook County

Thomas E. Lad
Ph: 312-864-6000

Thomas E. Lad
Principal Investigator

Rush University Medical Center

Dian Wang
Ph: 312-942-5498
Email: clinical_trials@rush.edu

Dian Wang
Principal Investigator

Weiss Memorial Hospital

Stuart A. Krauss
Ph: 773-564-5044

Stuart A. Krauss
Principal Investigator

Decatur

Decatur Memorial Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Peoria

OSF Saint Francis Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Rockford

SwedishAmerican Regional Cancer Center/ACT

Harvey E. Einhorn
Ph: 779-696-9400
Email: cancercare@swedishamerican.org

Harvey E. Einhorn
Principal Investigator

Springfield

Saint John's Hospital

Laurent Brard
Ph: 217-525-5666
Email: diana.weyhenmeyer@st-johns.org

Laurent Brard
Principal Investigator

Urbana

Carle Cancer Center

Sinisa Stanic
Ph: 800-446-5532

Sinisa Stanic
Principal Investigator

Indiana
Fort Wayne

Parkview Hospital Randallia

Brian K. Chang
Ph: 260-373-8888
Email: parkviewresearch@parkview.com

Brian K. Chang
Principal Investigator

Radiation Oncology Associates PC

Brian K. Chang
Ph: 260-373-8888
Email: parkviewresearch@parkview.com

Brian K. Chang
Principal Investigator

Indianapolis

IU Health Methodist Hospital

John A. Cox
Ph: 317-274-2552

John A. Cox
Principal Investigator

Iowa
Ames

McFarland Clinic PC-William R Bliss Cancer Center

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Kansas
Kansas City

University of Kansas Cancer Center

Parvesh Kumar
Ph: 913-945-7552
Email: ctnursenav@kumc.edu

Parvesh Kumar
Principal Investigator

Overland Park

Kansas City Cancer Centers-Southwest

Parvesh Kumar
Ph: 913-945-7552
Email: ctnursenav@kumc.edu

Parvesh Kumar
Principal Investigator

Topeka

Stormont-Vail Regional Health Center

David E. Einspahr
Ph: 785-270-4963

David E. Einspahr
Principal Investigator

Wichita

Via Christi Regional Medical Center

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Kentucky
Owensboro

Owensboro Health Mitchell Memorial Cancer Center

Ryan Jared Abel
Ph: 270-688-3691
Email: shawns@omhs.org

Ryan Jared Abel
Principal Investigator

Louisiana
Baton Rouge

Mary Bird Perkins Cancer Center

Augusto C. Ochoa
Ph: 504-568-2428
Email: emede1@lsuhsc.edu

Augusto C. Ochoa
Principal Investigator

New Orleans

Ochsner Medical Center Jefferson

Troy Gene Scroggins
Ph: 888-562-4763

Troy Gene Scroggins
Principal Investigator

Touro Infirmary

Augusto C. Ochoa
Ph: 504-568-2428
Email: emede1@lsuhsc.edu

Augusto C. Ochoa
Principal Investigator

Tulane University Health Sciences Center

William Russell Robinson
Ph: 504-988-6121

William Russell Robinson
Principal Investigator

Maryland
Annapolis

Anne Arundel Medical Center

Angel E. Torano
Ph: 443-481-1320
Email: kbodenhorn@aahs.org

Angel E. Torano
Principal Investigator

Baltimore

Saint Agnes Hospital

Richard S. Hudes
Ph: 410-368-2910

Richard S. Hudes
Principal Investigator

University of Maryland/Greenebaum Cancer Center

Young Kwok
Ph: 800-888-8823

Young Kwok
Principal Investigator

Bel Air

Upper Chesapeake Medical Center

Young Kwok
Ph: 800-888-8823

Young Kwok
Principal Investigator

Columbia

Central Maryland Radiation Oncology in Howard County

Young Kwok
Ph: 800-888-8823

Young Kwok
Principal Investigator

Glen Burnie

Tate Cancer Center

Young Kwok
Ph: 800-888-8823

Young Kwok
Principal Investigator

Salisbury

Peninsula Regional Medical Center

John Romeo Mansueti
Ph: 866-922-6237

John Romeo Mansueti
Principal Investigator

Massachusetts
Fall River

Saint Anne's Hospital

Jason Houn Lee
Ph: 508-674-5600ext2515

Jason Houn Lee
Principal Investigator

Hyannis

Cape Cod Hospital

Daniel Joseph Canaday
Ph: 508-862-5799

Daniel Joseph Canaday
Principal Investigator

Lowell

Lowell General Hospital

Matthew Strauss Katz
Ph: 978-788-7084
Email: ghincks@lowellgeneral.org

Matthew Strauss Katz
Principal Investigator

Plymouth

Beth Israel Deaconess Hospital-Plymouth

James Matthew Koomey
Ph: 508-830-2390
Email: cancerinfo@jordanhospital.org

James Matthew Koomey
Principal Investigator

Michigan
Ann Arbor

Saint Joseph Mercy Hospital

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Bay City

McLaren-Bay Region

Thomas P. Boike
Ph: 800-248-6777

Thomas P. Boike
Principal Investigator

Dearborn

Oakwood Hospital and Medical Center

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Detroit

Saint John Hospital and Medical Center

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Farmington Hills

21st Century Oncology-Farmington Hills

Jeffrey David Forman
Ph: 248-858-6215

Jeffrey David Forman
Principal Investigator

Flint

McLaren-Flint

Hesham El Gayar
Ph: 810-342-4071

Hesham El Gayar
Principal Investigator

Grand Rapids

Mercy Health Saint Mary's

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Spectrum Health at Butterworth Campus

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Lansing

Sparrow Hospital

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Lapeer

Great Lakes Cancer Institute-Lapeer Campus

Hesham El Gayar
Ph: 810-342-4071

Hesham El Gayar
Principal Investigator

Livonia

Saint Mary Mercy Hospital

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Mount Pleasant

McLaren-Central Michigan

Kiran Devisetty
Ph: 989-667-6257

Kiran Devisetty
Principal Investigator

Muskegon

Mercy Health Mercy Campus

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Owosso

McLaren Cancer Institute-Owosso

Hesham El Gayar
Ph: 810-342-4071

Hesham El Gayar
Principal Investigator

Petoskey

McLaren-Northern Michigan

Thomas P. Boike
Ph: 800-248-6777

Thomas P. Boike
Principal Investigator

Pontiac

Saint Joseph Mercy Oakland

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Saginaw

Saint Mary's of Michigan

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Troy

21st Century Oncology-Troy

Jeffrey David Forman
Ph: 248-858-6215

Jeffrey David Forman
Principal Investigator

Warren

Saint John Macomb-Oakland Hospital

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Minnesota
Bemidji

Sanford Clinic North-Bemidgi

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Duluth

Saint Luke's Hospital of Duluth

Steven R. Bonin
Ph: 888-823-5923
Email: ctsucontact@westat.com

Steven R. Bonin
Principal Investigator

Saint Louis Park

Park Nicollet Clinic - Saint Louis Park

Paul W. Sperduto
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Paul W. Sperduto
Principal Investigator

Mississippi
Jackson

University of Mississippi Medical Center

Srinivasan Vijayakumar
Ph: 601-815-6700

Srinivasan Vijayakumar
Principal Investigator

Pascagoula

Singing River Hospital

James E. Clarkson
Ph: 228-809-5292

James E. Clarkson
Principal Investigator

Missouri
Kansas City

Kansas City Cancer Center - South

Parvesh Kumar
Ph: 913-945-7552
Email: ctnursenav@kumc.edu

Parvesh Kumar
Principal Investigator

Kansas City Cancer Centers - North

Parvesh Kumar
Ph: 913-945-7552
Email: ctnursenav@kumc.edu

Parvesh Kumar
Principal Investigator

North Kansas City Hospital

Parvesh Kumar
Ph: 913-945-7552
Email: ctnursenav@kumc.edu

Parvesh Kumar
Principal Investigator

Lee's Summit

Kansas City Cancer Center-Lee's Summit

Parvesh Kumar
Ph: 913-945-7552
Email: ctnursenav@kumc.edu

Parvesh Kumar
Principal Investigator

Saint Louis

Barnes-Jewish West County Hospital

Jeff M. Michalski
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Jeff M. Michalski
Principal Investigator

Mercy Hospital Saint Louis

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Missouri Baptist Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Washington University School of Medicine

Jeff M. Michalski
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Jeff M. Michalski
Principal Investigator

Saint Peters

Siteman Cancer Center - Saint Peters

Jeff M. Michalski
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Jeff M. Michalski
Principal Investigator

Springfield

CoxHealth South Hospital

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Montana
Billings

Billings Clinic Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Great Falls

Benefis Healthcare- Sletten Cancer Institute

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Nebraska
Omaha

University of Nebraska Medical Center

Andrew Owen Wahl
Ph: 402-559-6941
Email: unmcrsa@unmc.edu

Andrew Owen Wahl
Principal Investigator

New Hampshire
Exeter

Exeter Hospital

Gary Miller Proulx
Ph: 800-439-3837

Gary Miller Proulx
Principal Investigator

Lebanon

Dartmouth Hitchcock Medical Center

Alan Charles Hartford
Ph: 800-639-6918
Email: cancer.research.nurse@dartmouth.edu

Alan Charles Hartford
Principal Investigator

New Jersey
Egg Harbor Township

AtlantiCare Surgery Center

James C. Wurzer
Ph: 609-748-7200

James C. Wurzer
Principal Investigator

Mount Holly

Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County

Lemuel S. Ariaratnam
Ph: 888-847-8823

Lemuel S. Ariaratnam
Principal Investigator

Sparta

Sparta Cancer Treatment Center

Maria Werner-Wasik
Ph: 215-955-6084

Maria Werner-Wasik
Principal Investigator

New Mexico
Las Cruces

Memorial Medical Center - Las Cruces

William M. Adler
Ph: 575-521-1554

William M. Adler
Principal Investigator

New York
Bay Shore

Southside Hospital

Louis Potters
Ph: 516-562-3467

Louis Potters
Principal Investigator

Brooklyn

The New York Methodist Hospital

Sameer Rafla-Demetrious
Ph: 718-780-5240

Sameer Rafla-Demetrious
Principal Investigator

Cooperstown

Mary Imogene Bassett Hospital

Naoyuki Gregory Saito
Ph: 607-547-3073
Email: diana.crean@bassett.org

Naoyuki Gregory Saito
Principal Investigator

Elmira

Arnot Ogden Medical Center/Falck Cancer Center

Chi K. Tsang
Ph: 607-271-7000

Chi K. Tsang
Principal Investigator

New Hyde Park

North Shore-LIJ Health System/Center for Advanced Medicine

Louis Potters
Ph: 516-562-3467

Louis Potters
Principal Investigator

North Carolina
Durham

Duke University Medical Center

William Robert Lee
Ph: 888-275-3853

William Robert Lee
Principal Investigator

Morehead City

The Coleman Radiation Center-Carteret General Hospital

Michael A. Papagikos
Ph: 910-251-1839

Michael A. Papagikos
Principal Investigator

Supply

South Atlantic Radiation Oncology

Michael A. Papagikos
Ph: 910-251-1839

Michael A. Papagikos
Principal Investigator

Wilmington

Coastal Carolina Radiation Oncology

Michael A. Papagikos
Ph: 910-251-1839

Michael A. Papagikos
Principal Investigator

Winston-Salem

Novant Health Forsyth Medical Center

Beverly Dawn Moose
Ph: 336-277-8887

Beverly Dawn Moose
Principal Investigator

Wake Forest University Health Sciences

Bart Alan Frizzell
Ph: 336-713-6771

Bart Alan Frizzell
Principal Investigator

North Dakota
Fargo

Sanford Medical Center-Fargo

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Ohio
Akron

Akron General Medical Center

Mitchel L. Fromm
Ph: 330-344-6348

Mitchel L. Fromm
Principal Investigator

Summa Akron City Hospital/Cooper Cancer Center

Desiree E. Doncals
Ph: 330-375-6101

Desiree E. Doncals
Principal Investigator

Barberton

Summa Barberton Hospital

Desiree E. Doncals
Ph: 330-375-6101

Desiree E. Doncals
Principal Investigator

Beachwood

UHHS-Chagrin Highlands Medical Center

Rodney J. Ellis
Ph: 800-641-2422

Rodney J. Ellis
Principal Investigator

Chardon

Geaugra Hospital

Rodney J. Ellis
Ph: 800-641-2422

Rodney J. Ellis
Principal Investigator

Chillicothe

Adena Regional Medical Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Cleveland

Case Western Reserve University

Rodney J. Ellis
Ph: 800-641-2422

Rodney J. Ellis
Principal Investigator

Columbus

The Mark H Zangmeister Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Elyria

Mercy Cancer Center-Elyria

Rodney J. Ellis
Ph: 800-641-2422

Rodney J. Ellis
Principal Investigator

Maumee

Toledo Clinic Cancer Centers-Maumee

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Medina

Summa Health Center at Lake Medina

Desiree E. Doncals
Ph: 330-375-6101

Desiree E. Doncals
Principal Investigator

Mentor

Lake University Ireland Cancer Center

Rodney J. Ellis
Ph: 800-641-2422

Rodney J. Ellis
Principal Investigator

Middleburg Heights

Southwest General Health Center Ireland Cancer Center

Rodney J. Ellis
Ph: 800-641-2422

Rodney J. Ellis
Principal Investigator

Parma

University Hospitals Parma Medical Center

Rodney J. Ellis
Ph: 800-641-2422

Rodney J. Ellis
Principal Investigator

Portsmouth

Southern Ohio Medical Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Ravenna

Robinson Radiation Oncology

Mitchel L. Fromm
Ph: 330-344-6348

Mitchel L. Fromm
Principal Investigator

Sandusky

Ireland Cancer Center at Firelands Regional Medical Center

Rodney J. Ellis
Ph: 800-641-2422

Rodney J. Ellis
Principal Investigator

Toledo

Mercy Saint Anne Hospital

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Westlake

UHHS-Westlake Medical Center

Rodney J. Ellis
Ph: 800-641-2422

Rodney J. Ellis
Principal Investigator

Oklahoma
Oklahoma City

University of Oklahoma Health Sciences Center

Terence S. Herman
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

Terence S. Herman
Principal Investigator

Oregon
Clackamas

Clackamas Radiation Oncology Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Grants Pass

Three Rivers Community Hospital

Gordon L. Metz
Ph: 541-789-6176

Gordon L. Metz
Principal Investigator

Medford

Providence Medford Medical Center

Gordon L. Metz
Ph: 541-789-6176

Gordon L. Metz
Principal Investigator

Rogue Valley Medical Center

Gordon L. Metz
Ph: 541-789-6176

Gordon L. Metz
Principal Investigator

Portland

Providence Portland Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Providence Saint Vincent Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Pennsylvania
Abington

Abington Memorial Hospital

Wayne H. Pinover
Ph: 215-481-2402

Wayne H. Pinover
Principal Investigator

Furlong

Fox Chase Cancer Center Buckingham

Eric Mark Horwitz
Ph: 215-728-4790

Eric Mark Horwitz
Principal Investigator

Gettysburg

Adams Cancer Center

Amit B. Shah
Ph: 877-441-7957

Amit B. Shah
Principal Investigator

Hanover

Cherry Tree Cancer Center

Amit B. Shah
Ph: 877-441-7957

Amit B. Shah
Principal Investigator

Hershey

Penn State Milton S Hershey Medical Center

Henry Wagner
Ph: 717-531-3779
Email: CTO@hmc.psu.edu

Henry Wagner
Principal Investigator

Philadelphia

Fox Chase Cancer Center

Eric Mark Horwitz
Ph: 215-728-4790

Eric Mark Horwitz
Principal Investigator

Pittsburgh

VA Pittsburgh Healthcare System

Kristina Gerszten
Ph: 412-688-6104

Kristina Gerszten
Principal Investigator

West Reading

Reading Hospital

Michael L. Haas
Ph: 610-988-9323

Michael L. Haas
Principal Investigator

York

WellSpan Health-York Hospital

Amit B. Shah
Ph: 877-441-7957

Amit B. Shah
Principal Investigator

South Carolina
Charleston

Medical University of South Carolina

David T. Marshall
Ph: 843-792-9321

David T. Marshall
Principal Investigator

Georgetown

Georgetown Hospital System

David T. Marshall
Ph: 843-792-9321

David T. Marshall
Principal Investigator

Greenville

Greenville Health System Cancer Institute-Eastside

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Greenwood

Self Regional Healthcare

David T. Marshall
Ph: 843-792-9321

David T. Marshall
Principal Investigator

Greer

Gibbs Cancer Center-Pelham

Patricia C. Griffin
Ph: 800-486-5941

Patricia C. Griffin
Principal Investigator

Hilton Head Island

The Radiation Oncology Center-Hilton Head/Bluffton

John A. Pablo
Ph: 800-622-6877

John A. Pablo
Principal Investigator

Spartanburg

Spartanburg Medical Center

Patricia C. Griffin
Ph: 800-486-5941

Patricia C. Griffin
Principal Investigator

Tennessee
Kingsport

Wellmont Holston Valley Hospital and Medical Center

Asheesh Shipstone
Ph: 423-578-8538

Asheesh Shipstone
Principal Investigator

Texas
Dallas

UT Southwestern/Simmons Cancer Center-Dallas

Raquibul Hannan
Ph: 214-648-7097

Raquibul Hannan
Principal Investigator

Fort Worth

The Klabzuba Cancer Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Galveston

University of Texas Medical Branch

Martin Colman
Ph: 409-772-1950
Email: clinical.research@utmb.edu

Martin Colman
Principal Investigator

Houston

Ben Taub General Hospital

Mark D. Bonnen
Ph: 713-798-1354
Email: burton@bcm.edu

Mark D. Bonnen
Principal Investigator

Memorial Hermann Memorial City Medical Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

League City

UTMB Cancer Center at Victory Lakes

Martin Colman
Ph: 409-772-1950
Email: clinical.research@utmb.edu

Martin Colman
Principal Investigator

Plano

Texas Oncology-Plano West

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

San Antonio

University of Texas Health Science Center at San Antonio

Tony Yuen Lung Eng
Ph: 210-450-3800
Email: CTO@uthscsa.edu

Tony Yuen Lung Eng
Principal Investigator

Sherman

Texas Cancer Center-Sherman

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Sugar Land

Texas Oncology Cancer Center Sugar Land

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Utah
American Fork

American Fork Hospital / Huntsman Intermountain Cancer Center

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Murray

Intermountain Medical Center

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Provo

Utah Valley Regional Medical Center

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Saint George

Dixie Medical Center Regional Cancer Center

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Salt Lake City

Huntsman Cancer Institute/University of Utah

Jonathan D. Tward
Ph: 801-581-4477
Email: clinical.trials@hci.utah.edu

Jonathan D. Tward
Principal Investigator

Utah Cancer Specialists-Salt Lake City

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Vermont
Bennington

Southwestern Vermont Medical Center

Alan Charles Hartford
Ph: 800-639-6918
Email: cancer.research.nurse@dartmouth.edu

Alan Charles Hartford
Principal Investigator

Berlin

Central Vermont Medical Center/National Life Cancer Treatment

Harold James Wallace
Ph: 802-656-4101

Harold James Wallace
Principal Investigator

Burlington

University of Vermont Medical Center

Harold James Wallace
Ph: 802-656-4101

Harold James Wallace
Principal Investigator

Saint Johnsbury

Norris Cotton Cancer Center-North

Alan Charles Hartford
Ph: 800-639-6918
Email: cancer.research.nurse@dartmouth.edu

Alan Charles Hartford
Principal Investigator

Virginia
Charlottesville

University of Virginia Cancer Center

Timothy Norman Showalter
Ph: 434-243-6143

Timothy Norman Showalter
Principal Investigator

Fishersville

Augusta Health Cancer Center

Robert M. Kyler
Ph: 540-689-7000

Robert M. Kyler
Principal Investigator

Hampton

Sentara Cancer Institute at Sentara CarePlex Hospital

Mark E. Shaves
Ph: 757-388-2406

Mark E. Shaves
Principal Investigator

Harrisonburg

Sentara Rockingham Memorial Hospital Hahn Cancer Center

Heather Anne White Morgan
Ph: 540-689-7000

Heather Anne White Morgan
Principal Investigator

Norfolk

Sentara Hospitals

Mark E. Shaves
Ph: 757-388-2406

Mark E. Shaves
Principal Investigator

Portsmouth

Naval Medical Center - Portsmouth

Edward F. Miles
Ph: 757-953-5939

Edward F. Miles
Principal Investigator

Roanoke

Oncology and Hematology Associates of Southwest Virginia

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Virginia Beach

Sentara Virginia Beach General Hospital

Mark E. Shaves
Ph: 757-388-2406

Mark E. Shaves
Principal Investigator

Washington
Federal Way

Saint Francis Hospital

Huong Thanh Pham
Ph: 206-342-6954
Email: vmmc.cancer_clinical_research@VirginiaMason.org

Huong Thanh Pham
Principal Investigator

Seattle

Virginia Mason CCOP

Huong Thanh Pham
Ph: 206-342-6954
Email: vmmc.cancer_clinical_research@VirginiaMason.org

Huong Thanh Pham
Principal Investigator

Virginia Mason Medical Center

Huong Thanh Pham
Ph: 206-342-6954
Email: vmmc.cancer_clinical_research@VirginiaMason.org

Huong Thanh Pham
Principal Investigator

Vancouver

PeaceHealth Southwest Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

West Virginia
Morgantown

West Virginia University Healthcare

Malcolm David Mattes
Ph: 304-293-2745
Email: sfilburn@hsc.wvu.edu

Malcolm David Mattes
Principal Investigator

Wisconsin
Appleton

Appleton Medical Center

Michael Edward Ray
Ph: 920-380-1500

Michael Edward Ray
Principal Investigator

Eau Claire

Mayo Clinic Health System Eau Claire Hospital - Luther Campus

Sakti Chakrabarti
Ph: 715-838-6356

Sakti Chakrabarti
Principal Investigator

Green Bay

Aurora BayCare Medical Center

Ellen L. Ziaja
Ph: 800-252-2990

Ellen L. Ziaja
Principal Investigator

Saint Mary's Hospital

James L. Leenstra
Ph: 920-433-8889

James L. Leenstra
Principal Investigator

Saint Vincent Hospital

James L. Leenstra
Ph: 920-433-8889

James L. Leenstra
Principal Investigator

Johnson Creek

UW Cancer Center Johnson Creek

Gregory M. Cooley
Ph: 920-699-3500
Email: lynda.persico@uwmf.wisc.edu

Gregory M. Cooley
Principal Investigator

La Crosse

Gundersen Lutheran Medical Center

Collin D. Driscoll
Ph: 608-775-2385
Email: cancerctr@gundluth.org

Collin D. Driscoll
Principal Investigator

Mayo Clinic Health System-Franciscan Healthcare

David J. Schwartz
Ph: 608-392-9462

David J. Schwartz
Principal Investigator

Marinette

Bay Area Medical Center

James L. Leenstra
Ph: 920-433-8889

James L. Leenstra
Principal Investigator

Mequon

Columbia Saint Mary's Hospital - Ozaukee

Craig Allan Schulz
Ph: 414-326-2675
Email: clinicaltrials@columbia-stmarys.org

Craig Allan Schulz
Principal Investigator

Milwaukee

Aurora Saint Luke's Medical Center

Ellen L. Ziaja
Ph: 800-252-2990

Ellen L. Ziaja
Principal Investigator

Columbia Saint Mary's Water Tower Medical Commons

Craig Allan Schulz
Ph: 414-326-2675
Email: clinicaltrials@columbia-stmarys.org

Craig Allan Schulz
Principal Investigator

Froedtert and the Medical College of Wisconsin

Colleen A. F. Lawton
Ph: 414-805-4380

Colleen A. F. Lawton
Principal Investigator

Zablocki Veterans Administration Medical Center

Elizabeth M. Gore
Ph: 414-805-4380

Elizabeth M. Gore
Principal Investigator

Oshkosh

Vince Lombardi Cancer Clinic - Oshkosh

Ellen L. Ziaja
Ph: 800-252-2990

Ellen L. Ziaja
Principal Investigator

Racine

Wheaton Franciscan Cancer Care - All Saints

James H. Taylor
Ph: 414-874-4541
Email: Kelli.holton@wfhc.org

James H. Taylor
Principal Investigator

Sheboygan

Vince Lombardi Cancer Clinic-Sheboygan

Ellen L. Ziaja
Ph: 800-252-2990

Ellen L. Ziaja
Principal Investigator

Sturgeon Bay

Door County Cancer Center

James L. Leenstra
Ph: 920-433-8889

James L. Leenstra
Principal Investigator

Summit

Aurora Medical Center in Summit

Ellen L. Ziaja
Ph: 800-252-2990

Ellen L. Ziaja
Principal Investigator

West Allis

Aurora West Allis Medical Center

Ellen L. Ziaja
Ph: 800-252-2990

Ellen L. Ziaja
Principal Investigator

Wisconsin Rapids

Riverview Hospital

Gregory M. Cooley
Ph: 920-699-3500
Email: lynda.persico@uwmf.wisc.edu

Gregory M. Cooley
Principal Investigator

Canada

Alberta
Calgary

Tom Baker Cancer Centre

Michael Augustine Sia
Ph: 403-521-3433

Michael Augustine Sia
Principal Investigator

Edmonton

Cross Cancer Institute

Brita Lavender Danielson
Ph: 780-432-8500

Brita Lavender Danielson
Principal Investigator

Ontario
Toronto

Odette Cancer Centre- Sunnybrook Health Sciences Centre

Hans Tse Chung
Ph: 416-480-5000

Hans Tse Chung
Principal Investigator

Quebec
Montreal

CHUM - Hopital Notre-Dame

Jean-Paul Bahary
Ph: 514-890-8000ext23611
Email: sylvie.beaudoin.chum@ssss.gouv.qc.ca

Jean-Paul Bahary
Principal Investigator

McGill University Department of Oncology

Fabio Luis Biagini Cury
Ph: 514-398-1444
Email: penny.chipman@mcgill.ca

Fabio Luis Biagini Cury
Principal Investigator

Quebec City

CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)

Eric Vigneault
Ph: 418-525-4444

Eric Vigneault
Principal Investigator

Saskatchewan
Regina

Allan Blair Cancer Centre

Evgeny Sadikov
Ph: 306-766-2213

Evgeny Sadikov
Principal Investigator

Saskatoon

Saskatoon Cancer Centre

Ali Abdel El-Gayed
Ph: 306-655-2914

Ali Abdel El-Gayed
Principal Investigator

Republic of Singapore

Singapore

National Cancer Centre

Terence Wee Kiat Tan
Ph: 65 6225 5655
Email: cancerhelpline@nccs.com.sg

Terence Wee Kiat Tan
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01368588

Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.